Product Name: IL-17A Antibody
Species Reactivity: Mouse
Tested Applications: ELISA, WB
Applications: ELISA:Indirect:To detect mIL-17A by indirect ELISA (using 100 μL/well antibody solution) a concentration of 0.5 – 2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2 – 0.4 ng/well of recombinant mIL-17A.SandwichTo detect mIL-17A by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5 – 2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with our biotinylated Anti-Murine IL-17A as a detection antibody, allows the detection of at least 0.2 – 0.4 ng/well of recombinant mIL-17A. Western Blot:To detect mIL-17A by Western Blot analysis this antibody can be used at a concentration of 0.1 – 0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant mIL-17A is 1.5 – 3.0 ng/lane, under either reducing or non-reducing conditions.
User Note: Centrifuge vial prior to opening.
Predicted Molecular Weight:
Immunogen: Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant mIL-17A (murine IL-17A). Murine IL-17A specific antibody was purified by affinity chromatography employing immobilized mIL-17A matrix.
Host Species: Rabbit
Purification:
Physical State: Lyophilized
CAS NO.: 61-78-9
Product: Nastorazepide
Buffer:
Concentration:
Storage Conditions: IL-17A antibody is stable for at least 2 years from date of receipt at -20˚C. The reconstituted antibody is stable for at least two weeks at 2-8˚C. Frozen aliquots are stable for at least 6 months when stored at -20˚C. Avoid repeated freeze-thaw cycles.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: Il17, Ctla8, IL-17, Ctla-8, IL-17A, Il17, Interleukin-17A, Cytotoxic T-lymphocyte-associated antigen 8
Accession NO.: Q62386
Protein Ino: 2498482
Official Symbol: Il17a
Geneid: 16171
Background:
PubMed ID:http://aac.asm.org/content/26/2/145.abstract
